Vancomycin and Oritavancin Have Different Modes of Action in Enterococcus faecium

Journal of Molecular Biology

Volumn 392, Issue 5, 2009, Pages 1178-1191

  Patti, Gary J ^a   Kim, Sung Joon ^a   Yu, Tsyr Yan ^a   Dietrich, Evelyne ^b   Tanaka, Kelly S E ^b   Parr Jr , Thomas R ^b   Far, Adel Rafai ^b   Schaefer, Jacob ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b Targanta Therapeutics Inc   (Canada)

Author keywords

bacterial cell wall; glycopeptide antibiotics; peptidoglycan; REDOR; solid state NMR

Indexed keywords

ALANINE; ANTIBIOTIC AGENT; CARBON 13; GLYCOSYLTRANSFERASE; LYSINE; ORITAVANCIN; PEPTIDOGLYCAN; VANCOMYCIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BINDING AFFINITY; CELL WALL; CONTROLLED STUDY; CROSS LINKING; DRUG BINDING SITE; DRUG EXPOSURE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; ENZYME INHIBITION; HYPOTHESIS; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; STAPHYLOCOCCUS; WHOLE CELL;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS FAECIUM;

ANTI-BACTERIAL AGENTS; CARBON ISOTOPES; CELL WALL; ENTEROCOCCUS FAECIUM; FLUORINE; GLYCOPEPTIDES; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR STRUCTURE; PEPTIDOGLYCAN; VANCOMYCIN;

EID: 70249121735     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2009.06.064     Document Type: Article

References (41)

1. Levine D.P. Vancomycin: a history. Clin. Infect. Dis. 42 Suppl. 1 (2006) S5-S12
2. Arias C.A., and Murray B.E. Emergence and management of drug-resistant enterococcal infections. Expert Rev. Anti-Infect. Ther. 6 (2008) 637-655
3. McGregor J.C., Kim P.W., Perencevich E.N., Bradham D.D., Furuno J.P., Kaye K.S., et al. Utility of the Chronic Disease Score and Charlson Comorbidity Index as comorbidity measures for use in epidemiologic studies of antibiotic-resistant organisms. Am. J. Epidemiol. 161 (2005) 483-493
4. Allen N.E., and Nicas T.I. Mechanism of action of oritavancin and related glycopeptide antibiotics. FEMS Microbiol. Rev. 26 (2003) 511-532
5. Mercier R.C., and Hrebickova L. Oritavancin: a new avenue for resistant Gram-positive bacteria. Expert Rev. Anti-Infect. Ther. 3 (2005) 325-332
6. Barrett J.F. Recent developments in glycopeptide antibacterials. Curr. Opin. Invest. Drugs 6 (2005) 781-790
7. Beauregard D.A., Williams D.H., Gwynn M.N., and Knowles D.J. Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics. Antimicrob. Agents Chemother. 39 (1995) 781-785
8. Courvalin P. Vancomycin resistance in Gram-positive cocci. Clin. Infect. Dis. 42 Suppl 1 (2006) S25-S34
9. Mercier R.C., Stumpo C., and Rybak M.J. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium. J. Antimicrob. Chemother. 50 (2002) 19-24
10. Arthur M., Depardieu F., Reynolds P., and Courvalin P. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci. Antimicrob. Agents Chemother. 43 (1999) 1875-1880
11. Anderson J.S., Matsuhashi M., Haskin M.A., and Strominger J.L. Biosynthesis of the peptidoglycan of bacterial cell walls: II. Phospholipid carriers in the reaction sequence. J. Biol. Chem. 242 (1967) 3180-3190
12. Matsuhashi M., Dietrich C.P., and Strominger J.L. Incorporation of glycine into the cell wall glycopeptide in Staphylococcus aureus: role of sRNA and lipid intermediates. Proc. Natl Acad. Sci. USA 54 (1965) 587-594
13. Shiozawa H., Chia B.C., Davies N.L., Zerella R., and Williams D.H. Cooperative binding interactions of glycopeptide antibiotics. J. Am. Chem. Soc. 124 (2002) 3914-3919
14. Ge M., Chen Z., Onishi H.R., Kohler J., Silver L.L., Kerns R., et al. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding d-Ala-d-Ala. Science 284 (1999) 507-511
15. Billot-Klein D., Shlaes D., Bryant D., Bell D., van Heijenoort J., and Gutmann L. Peptidoglycan structure of Enterococcus faecium expressing vancomycin resistance of the VanB type. Biochem. J. 313 Pt 3 (1996) 711-715
16. Brotz H., Bierbaum G., Reynolds P.E., and Sahl H.G. The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Eur. J. Biochem. 246 (1997) 193-199
17. Goldman R.C., Baizman E.R., Longley C.B., and Branstrom A.A. Chlorobiphenyl-desleucyl-vancomycin inhibits the transglycosylation process required for peptidoglycan synthesis in bacteria in the absence of dipeptide binding. FEMS Microbiol. Lett. 183 (2000) 209-214
18. Vollmer W., Blanot D., and de Pedro M.A. Peptidoglycan structure and architecture. FEMS Microbiol. Rev. 32 (2008) 149-167
19. Patti G.J., Kim S.J., and Schaefer J. Characterization of the peptidoglycan of vancomycin-susceptible Enterococcus faecium. Biochemistry 47 (2008) 8378-8385
20. 15N labeling. J. Mol. Biol. 357 (2006) 1253-1262
21. Schleifer K.H., and Kandler O. Peptidoglycan types of bacterial cell walls and their taxonomic implications. Bacteriol. Rev. 36 (1972) 407-477
22. Patti G.J., Chen J., Schaefer J., and Gross M.L. Characterization of structural variations in the peptidoglycan of vancomycin-susceptible Enterococcus faecium: understanding glycopeptide-antibiotic binding sites using mass spectrometry. J. Am. Soc. Mass Spectrom. 19 (2008) 1467-1475
23. Hasper H.E., Kramer N.E., Smith J.L., Hillman J.D., Zachariah C., Kuipers O.P., et al. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. Science 313 (2006) 1636-1637
24. Breukink E., and de Kruijff B. Lipid II as a target for antibiotics. Nat. Rev. Drug Discov. 5 (2006) 321-332
25. 2 labeling. J. Magn. Reson. 178 (2006) 1-10
26. 15N labeling. J. Biol. Chem. 280 (2005) 39238-39245
27. Molitor E., Kluczny C., Brotz H., Bierbaum G., Jack R., and Sahl H.G. Effects of the lantibiotic mersacidin on the morphology of staphylococci. Zentralbl. Bakteriol. 284 (1996) 318-328
28. Salton M.R.J. The Bacterial Cell Wall (1964), Elsevier, Amsterdam, The Netherlands
29. Kim S.J., Cegelski L., Stueber D., Singh M., Dietrich E., Tanaka K.S., et al. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. J. Mol. Biol. 377 (2008) 281-293
30. 19F} rotational-echo double resonance. Biochemistry 45 (2006) 5235-5250
31. al-Obeid S., Collatz E., and Gutmann L. Mechanism of resistance to vancomycin in Enterococcus faecium D366 and Enterococcus faecalis A256. Antimicrob. Agents Chemother. 34 (1990) 252-256
32. Gutmann L., Billot-Klein D., al-Obeid S., Klare I., Francoual S., Collatz E., and van Heijenoort J. Inducible carboxypeptidase activity in vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 36 (1992) 77-80
33. Allen N.E., LeTourneau D.L., and Hobbs Jr. J.N. The role of hydrophobic side chains as determinants of antibacterial activity of semisynthetic glycopeptide antibiotics. J. Antibiot. (Tokyo) 50 (1997) 677-684
34. Guillion T.S., and Schaefer J. Detection of weak heteronuclear dipolar coupling by rotational-echo double-resonance nuclear magnetic resonance. Adv. Magn. Reson. 13 (1989) 57-83
35. Kim S.J., Matsuoka S., Patti G.J., and Schaefer J. Vancomycin derivative with damaged d-Ala-d-Ala binding cleft binds to cross-linked peptidoglycan in the cell wall of Staphylococcus aureus. Biochemistry 47 (2008) 3822-3831
36. Kim S.J., and Schaefer J. Hydrophobic side-chain length determines activity and conformational heterogeneity of a vancomycin derivative bound to the cell wall of Staphylococcus aureus. Biochemistry 47 (2008) 10155-10161
37. Boneca I.G., Huang Z.H., Gage D.A., and Tomasz A. Characterization of Staphylococcus aureus cell wall glycan strands, evidence for a new beta-N-acetylglucosaminidase activity. J. Biol. Chem. 275 (2000) 9910-9918
38. de Jonge B.L., Gage D., and Handwerger S. Peptidoglycan composition of vancomycin-resistant Enterococcus faecium. Microb. Drug Resist. 2 (1996) 225-229
39. Hayhurst E.J., Kailas L., Hobbs J.K., and Foster S.J. Cell wall peptidoglycan architecture in Bacillus subtilis. Proc. Natl Acad. Sci. USA 105 (2008) 14603-14608
40. Schaefer, J. & McKay, R. A. (1999). Multi-tuned single coil transmission line probe for nuclear magnetic resonance spectrometer, U.S. Patent 5861748.
41. 19F} rotational-echo double-resonance NMR. J. Polym. Sci., Part B: Polym. Phys. 44 (2006) 2760-2775